PAR3 COST-EFFECTIVENESS OF LUMIRACOXIB COMPARED TO CELECOXIB FOR THE TREATMENT OF OSTEOARTHRITIS IN CANADA  by Sambrook, JC et al.
A117Abstracts
ical activity level, exacerbations, and school absences). The
impact of the following factors was investigated: family income
adequacy, parent education, parent employment, ethnicity,
parent immigration, language, parent marital status, and physi-
cal environment characteristics. The CPACG and Global Initia-
tive for Asthma (GINA) guideline deﬁnitions of asthma control
were compared. RESULTS: Only 11% of patients met the
requirements for acceptable control by satisfying all six para-
meters, while 20% satisﬁed ﬁve parameters, and 69% satisﬁed
four or fewer parameters. The multiple regressions indicated that
income adequacy had an impact on asthma control. Children
from families in the middle income adequacy quintile tended 
to have worse control. Higher numbers of asthma triggers,
increased physician or specialist visits, and daily use of anti-
inﬂammatories, were associated with lower levels of control. The
CPACG and GINA guidelines had a high level of agreement
(Weighted kappa = 0.74, p < 0.0001), although it was more dif-
ﬁcult to achieve acceptable asthma control in the CPACG guide-
lines. CONCLUSION: Despite the established effectiveness of
inhaled corticosteroids in the prevention of asthma exacerba-
tions, poor control remains a problem which was affected by
family income adequacy.
ARTHRITIS—Clinical Outcomes Studies
PAR1
MORTALITY RATE OF PATIENTS WITH RHEUMATOID
ARTHRITIS, PSORIASIS, CROHN’S DISEASE AND ULCERATIVE
COLITIS IN THE UNITED KINGDOM
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OBJECTIVES: Rheumatoid arthritis (RA), psoriasis (PS),
Crohn’s disease (CD) and ulcerative colitis (UC) are autoimmune
related diseases. The purpose of this study was to estimate the
mortality rate of patients for each of these four conditions, rel-
ative to the overall population, adjusting for age and sex differ-
ences of the each patient group. METHODS: The analysis was
based on the THIN database for 2004. This data source is based
on the registration in GP-practices for a 4% representative
sample of the overall UK population. From the overall-popula-
tion sample (n = 2.278.100), patients were identiﬁed based on
the READ codes for each of these conditions in the previous 4
years. A subgroup of severe cases was identiﬁed, based on pre-
vious drug treatment. The standardised mortality ratio (SMR),
deﬁned as the proportion of the observed number of deaths and
the expected number, based on the age and gender speciﬁc 
mortality rates for the overall population, was calculated for
each patient group. 95% conﬁdence intervals were calculated.
RESULTS: 2% of the studied population suffers from one or
more of the four diseases: RA (0.44%), PS (1.3%), CD (0.14%)
or UC (0.16%). The SMR for all four disease conditions com-
bined was signiﬁcantly higher (132 [122,143]) compared to the
global UK population. Within the four groups, RA (158
[139,179]), CD (165 [108,241]) and PS (116 [103,130]) all
showed statistically increased mortality. The SMR was (ns)
higher for UC (122, [89,163]). Within each of these disease
groups, mortality was higher for severe patients, but did not
reach statistical signiﬁcance, possibly due to the relatively small
sample size of these subgroups. CONCLUSION: Patients suf-
fering from Crohn’s disease and rheumatoid arthritis have a 60%
increased mortality compared to the overall UK population.
Mortality is about 20% higher for patients with psoriasis and
ulcerative colitis.
ARTHRITIS—Cost Studies
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OBJECTIVES: To assess the health care utilization and associ-
ated costs for osteoarthritis (OA) patients, depending on the
primary drug prescribed for pain management. METHODS: A
claims database of privately insured patients (covering 31
employers, 1999–2004) was used to identify OA patients (ICD-
9-CM 715.XX) OA patients were categorized by primary pain
drug treatment—deﬁned as greatest days supply, 2003–2004—
for pain management (tramadol, acetaminophen w/codeine,
Cox-IIs, NSAIDS, short-acting opioids). A tramadol monother-
apy cohort was also constructed in which patients were pre-
scribed only tramadol for their pain (i.e., these patients did not
receive any of the other primary pain drugs listed above.) Mean
annual per patient health care costs were calculated for each drug
treatment cohort from a private payer’s perspective. RESULTS:
OA patients (n = 32,043) were often prescribed multiple drugs
simultaneously and/or sequentially to manage pain. Average
annual direct medical costs for OA patients were $8602 (ranging
from $6011 to $13,964 depending on the drug treatment
cohort). Average annual drug costs for OA patients were $2941
(ranging from $2108 to $8498 depending on the drug treatment
cohort). The tramadol monotherapy cohort had lower costs than
other cohorts. Cohort cost differences reﬂect, in part, more
severe comorbidity proﬁle and complex temporal treatment pat-
terns. CONCLUSION: Average annual direct costs of OA
patients were $11,543, which varies by drug treatment cohort.
OA patients use multiple simultaneously and/or sequentially to
treat their pain. Prescribing tramadol earlier to treat OA may
reduce therapy switching and associated costs and a once-a-day
version of tramadol may offer additional convenience, tolerabil-
ity and sleep improvement beneﬁts for OA patients. Future
research is needed to identify the temporal patterns of tramadol
use and associated outcomes.
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OBJECTIVES: To estimate incremental cost-utility ratios for
lumiracoxib relative to celecoxib for treating osteoarthritis (OA)
in Canada. Secondary comparators including six common treat-
ment algorithms (non-steroidal anti-inﬂammatory drugs with
and without proton pump inhibitors) were also evaluated.
METHODS: An existing Markov model with 3 month cycle
lengths and 5 year time horizon was adapted for Canada. Analy-
ses were performed from the third-party perspective of the
Ontario Ministry of Health. Treatments were assumed to be
equally efﬁcacious in treating symptoms of OA. Data on differ-
ences in rates of gastrointestinal (GI) and other (renal, skin,
hepatic) adverse events were obtained from published random-
ized trials. Quality-adjusted life years (QALYs) were calculated
separately for subgroups deﬁned a priori for age, sex, aspirin use,
and history of GI bleed. Common treatment pathways were
elicited from clinical experts. Costs of hospitalizations, labora-
tory tests, professional fees, and medications were obtained from
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published sources. Societal utility scores were obtained from a
standard gamble study conducted in Canadians. Costs (2006
CDN dollars) and outcomes were discounted at 5%. Incremen-
tal cost-effectiveness ratios (ICERs) were estimated relative to
lumiracoxib. Sensitivity analyses were conducted for all input
parameters to identify inﬂuential inputs. RESULTS: Lumiracoxib
was more effective and less costly (i.e. dominated) in all sub-
groups when compared to celecoxib. Compared to celecoxib,
lumiracoxib was predicted to reduce clinical and complicated
events in non-ASA patients by 10 and 55% respectively. ICERs
ranged from −$11,253/QALY to −$187,203/QALY for average
risk patients and became more favorable over the cohort’s life-
time. Results were most sensitive to the utility of arthritis and
adverse event rates but the interpretation was robust. Compared
to the majority of secondary treatment algorithms, lumiracoxib
also had an attractive cost-effectiveness proﬁle. CONCLUSION:
From an economic perspective, lumiracoxib is an attractive treat-
ment choice for Canadian OA patients and is more cost-effec-
tive than celecoxib.
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ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR
INHIBITORS IN THE TREATMENT OF ANKYLOSING
SPONDYLITIS
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OBJECTIVES: Ankylosing spondylitis (AS) is a chronic, pro-
gressive inﬂammatory form of arthritis with annual estimated
costs of US $6720 per patient. Given the chronic nature of AS
and the high costs of the newer treatments such as tumor necro-
sis factor (TNF) inhibitors, the goal of this study is to conduct
an incremental cost-effectiveness analysis of TNF inhibitors com-
pared with a standard treatment option in patients with AS.
METHODS: A Markov simulation model (one-year) was used
to evaluate the incremental cost-effectiveness of three treatments
in patients with AS: 1) etanercept; 2) inﬂiximab; and 3) standard
treatment (NSAIDs). The decision model assumed a base-case
population of 40 year-old men and the efﬁcacy and withdrawal
data were based on clinical trials of respective drugs. The effec-
tiveness measure was Assessments in Ankylosing Spondylitis
20% Response data (ASAS 20) and the incremental cost-effec-
tiveness ratio (ICER) was calculated as additional cost per ASAS
20, compared with the next most expensive option. The study
was conducted from a payer’s perspective and the cost of treat-
ment with each agent included medication costs, monitoring
costs, infusion administration costs, and physician visit costs.
One-way sensitivity analyses were conducted to test the robust-
ness of study results. RESULTS: The annual costs for standard
treatment, etanercept, and inﬂiximab were $3000, $12,000 and
$13,000, respectively. The ICER of etanercept compared with
standard treatment was $10,860.96/ASAS 20, while the ICER 
of inﬂiximab compared with standard treatment was
$26,314.59/ASAS 20. One-way sensitivity analyses indicated
that the conclusions were relatively stable to variations in model
assumptions. CONCLUSION: The introduction of TNF
inhibitors has represented a signiﬁcant advance in the available
treatments for patients with AS. Thus, demonstrating the cost-
effectiveness of these new treatments can be a critical factor in
determining the acceptability of these new therapies especially
since these agents may offer improved function and signiﬁcant
downstream economic savings.
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OBJECTIVES: To compare the cost-effectiveness of once-daily
tramadol extended-release (ER) and branded and generic tra-
madol immediate-release (IR) formulations for the treatment of
chronic osteoarthritis pain from a managed care payer perspec-
tive. METHODS: A one-year model was constructed to compare
the cost per percent pain reduction using tramadol formulations
for treating chronic osteoarthritis pain. Prevalence, clinical efﬁ-
cacy, and model assumptions were based on product labels, clin-
ical study reports, and published literature. Overall costs
included: drug costs (Red Book), concomitant drug costs to treat
adverse events (AEs), and resource utilization costs (ofﬁce visits,
emergency room visits, and inpatient hospitalizations). Effec-
tiveness was deﬁned as percent pain reduction, calculated as
mean change from baseline in pain intensity score (ER 35.37%
and IR 29.63%). Based on the literature a 30% pain reduction
is considered clinically meaningful (Farrar 2001). In the cost-
effectiveness analysis, a linear relationship across all costs and
effectiveness ranges was assumed to extrapolate costs per clini-
cally meaningful pain reduced (30%). Univariate sensitivity
analyses were conducted to determine model inputs with the
most inﬂuence on model results. RESULTS: The overall annual
cost of therapy per patient was $8238 (ER), $8120 (branded IR),
and $7561 (generic IR). The annual patient cost for every per-
centage pain reduction was lowest for ER ($232.90) followed by
generic IR ($255.18) and branded IR ($274.04). The incremen-
tal cost-effectiveness ratio (ICER) for ER versus branded IR was
$20.48 and the ICER for ER versus generic IR was $118.00 per
percentage pain reduction. Sensitivity analyses indicated that the
drug cost for ER has the most inﬂuence on the cost-effectiveness
ratio. CONCLUSION: This analysis suggests the drug acquisi-
tion cost of ER may be offset by its clinical effectiveness, result-
ing to be a more cost-effective treatment alternative.
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OBJECTIVES: To evaluate the all-cause health care costs among
patients with PsA, who received anti-TNF treatment.
METHODS: A retrospective study using the PharMetrics data-
base, compiled from managed care plans throughout the United
States from January 2000 through June 2005, was conducted.
Patients continuously enrolled for 6 months pre- and 12 months
post-diagnosis, and having 2 distinct claims of PsA, were
included in the study. A 6-month period prior to the index diag-
nosis date was used to establish anti-TNF and/or MTX treat-
ment, naïve patients, and to identify new PsA patients. Per
patient per month treatment (PPPM) costs was calculated for
patients during their treatment period. The cost of adverse events
could not be identiﬁed separately in this analysis. A multivariate
model was used to adjust for covariates including age, gender,
number of medical visits, Charlson Co-morbidity Index, and pre-
period health care costs. RESULTS: A total of 357 patients with
PsA were included in the analysis. Nearly half of the patients
